Dominik Hlauschek
Overview
Explore the profile of Dominik Hlauschek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless A, Pond G, Vandermeer L, et al.
J Med Internet Res
. 2025 Mar;
27:e66821.
PMID: 40053790
Background: Insufficient patient accrual is a major challenge in clinical trials and can result in underpowered studies, as well as exposing study participants to toxicity and additional costs, with limited...
2.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C, et al.
Breast
. 2025 Feb;
80:104415.
PMID: 39985843
Background: The Clinical Treatment Score post-5 years (CTS5) is a clinicopathological tool designed to estimate late distant recurrence (LDR) in hormone receptor-positive (HR+) breast cancer patients after 5 years of...
3.
Rinnerthaler G, Egle D, Bartsch R, Schmitt C, Petzer A, Balic M, et al.
Nat Cancer
. 2025 Jan;
6(1):41-50.
PMID: 39820125
The role of anthracyclines in the treatment of early breast cancer (EBC) is increasingly being challenged, especially in de-escalation strategies. However, owing to their immunogenic effects, anthracyclines are promising combination...
4.
Singer C, Jahn S, Hlauschek D, Heber U, Mang-Manger C, Egle D, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39757921
No abstract available.
5.
Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E, et al.
Breast Cancer Res
. 2024 Oct;
26(1):140.
PMID: 39375745
Background: Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive...
6.
7.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C, et al.
Breast Cancer Res Treat
. 2024 May;
206(2):441.
PMID: 38704775
No abstract available.
8.
Hlauschek D, Gnant M
Ann Surg Treat Res
. 2024 Apr;
106(4):237-238.
PMID: 38586550
No abstract available.
9.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C, et al.
Breast Cancer Res Treat
. 2024 Jan;
205(2):227-239.
PMID: 38273214
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of...
10.
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol
. 2023 Aug;
41(33):5118-5130.
PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...